Literature DB >> 6286114

Tumoricidal effect of macrophages exposed to adriamycin in vivo or in vitro.

F Martin, A Caignard, O Olsson, J F Jeannin, A Leclerc.   

Abstract

Peritoneal macrophages from BD IX rats collected 24 hr after an i.p. injection of ADriamycin (10 mg/kg) were cytotoxic to syngeneic cancer cells in culture. In contrast, incubation in vitro in Adriamycin solutions did not evoke tumoricidal activity in peritoneal macrophages, whatever the incubation time (from 1 to 24 hr) and the Adriamycin concentration (from 1 ng to 100 micrograms/ml). Macrophages incubated with Adriamycin in vitro accumulated the drug in their nuclei, whereas macrophages from animals receiving Adriamycin in vivo accumulated it is cytoplasmic vacuoles. Early observation of peritoneal cells after in vivo exposure to Adriamycin shows that Adriamycin is concentrated in mast cell granules which are released and then phagocytosed by peritoneal macrophages. Mast cells exposed to Adriamycin in vitro can induce macrophages to become cytotoxic. These facts explain the difference between macrophages exposed to Adriamycin in vivo and in vitro. Adriamycin fluorescence appears in nuclei of cancer cells incubated with in vivo-labeled macrophages, suggesting that macrophages can directly transfer the drug into cancer cells and therefore play a role in the Adriamycin antitumor effect.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6286114

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  14 in total

1.  Enhanced susceptibility of target KMT-17 cells to activated macrophages by treatment with the antitumor agent bleomycin.

Authors:  Z Y Xu; M Hosokawa; K Morikawa; H Kobayashi
Journal:  Cancer Immunol Immunother       Date:  1986       Impact factor: 6.968

2.  4'-O-tetrahydropyranyl adriamycin (THP-ADM)-induced modifications of murine peritoneal macrophages.

Authors:  A Bravo-Cuellar; G Mathé; S Orbach-Arbouys
Journal:  Med Oncol Tumor Pharmacother       Date:  1989

3.  Cancer chemotherapeutics as immunomodulators.

Authors:  F Spreafico; A Vecchi; F Colotta; A Montovani
Journal:  Springer Semin Immunopathol       Date:  1985

4.  Ability of doxorubicin-loaded nanoparticles to overcome multidrug resistance of tumor cells after their capture by macrophages.

Authors:  C E Soma; C Dubernet; G Barratt; F Nemati; M Appel; S Benita; P Couvreur
Journal:  Pharm Res       Date:  1999-11       Impact factor: 4.200

5.  Methods for amplifying the induction and expression of cytotoxic response in vitro to syngeneic and autologous freshly-isolated solid tumors of mice.

Authors:  E Kedar; E Chriqui-Zeira; S Mitelman
Journal:  Cancer Immunol Immunother       Date:  1984       Impact factor: 6.968

6.  The synergistic tumoricidal activity of anticancer drugs and oxidative burst-triggered macrophages.

Authors:  S Marcovitch; Y Keisari
Journal:  Cancer Immunol Immunother       Date:  1985       Impact factor: 6.968

7.  Induction of activated macrophages by intraperitoneal injection of mitomycin C in mice.

Authors:  H Shindo; T Ogura; T Masuno; S Hayashi; S Kishimoto
Journal:  Cancer Immunol Immunother       Date:  1985       Impact factor: 6.968

8.  Potential usefulness of quinine to circumvent the anthracycline resistance in clinical practice.

Authors:  B Chauffert; H Pelletier; C Corda; E Solary; L Bedenne; D Caillot; F Martin
Journal:  Br J Cancer       Date:  1990-09       Impact factor: 7.640

9.  Superior therapeutic activity of liposome-associated adriamycin in a murine metastatic tumour model.

Authors:  A Gabizon; D Goren; Z Fuks; A Meshorer; Y Barenholz
Journal:  Br J Cancer       Date:  1985-05       Impact factor: 7.640

10.  Amiodarone is more efficient than verapamil in reversing resistance to anthracyclines in tumour cells.

Authors:  B Chauffert; D Rey; B Coudert; M Dumas; F Martin
Journal:  Br J Cancer       Date:  1987-08       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.